The pharmacological company Moderna announced on Wednesday that preliminary results of human studies show that both the third dose of its preparation against COVID-19 and its other, experimental vaccine – increases resistance to the Brazilian and South African variants of the coronavirus.
The third dose also strengthened protection against the basic version of the coronavirus, Moderna reported.
It is a study involving 40 people, which used both the already used Moderny vaccine and the version developed by this company to provide protection against the so-called South African variant of the coronavirus. Moderna is also examining a preparation that combines both of these specificities.
Main photo source: PAP / Leszek Szymański